Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

  • Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    • News

  • Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology
    Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology
    • News

  • Harris Technology boosts retail margins in FY25 through growth of refurbished tech
    Harris Technology boosts retail margins in FY25 through growth of refurbished tech
    • News

  • Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.
    Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.
    • News

  • dorsaVi Powers Ahead with High-Speed RRAM for Smarter Wearables and Edge AI
    dorsaVi Powers Ahead with High-Speed RRAM for Smarter Wearables and Edge AI
    • News

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

Healthia acquires 3 hand therapy clinics to service rising allied health demand

  • In News
  • June 6, 2022
  • Samantha Freidin
Healthia acquires 3 hand therapy clinics to service rising allied health demand

Working from home has its perks, but it most definitely has its downsides. No irritating colleague small talks also means less breaks. Limited space means working from the not-so-ergonomic dining table, or a greater sin- the couch.

The combination of couch working and a propensity to not take regular breaks has led to the recurrence of my old shoulder issue, now a full blown compressed-nerve-with-radiating-pain-through-my-hand situation. Ouch.

Allied health company Healthia (ASX: HLA) has obviously heard the ibuprofen packet opening, having acquired two hand therapy clinics for us battered and bruised home based workers.

With the goal of becoming Australia’s largest and most diversified allied health portfolio, Healthia has an aggressive acquisition strategy, deploying a minimum of $20 million per year on acquiring the best allied health clinics.

The Company will integrate both Bay Hand Therapy in Beaumaris, Victoria and Sunshine Coast Hand Therapy in Queensland into their network. The acquisitions are expected to contribute an annualised  revenue of $1.58 million and $0.43m underlying EBITDA to Healthia.  Upfront cash consideration of $1.26 million will be payable to vendors as well as$0.44 million of Clinic Class Shares where clinic owners can maintain equity and profit share for the clinics to be acquired by Healthia at an attractive EBITDA multiple of 3.95x when Healthia has been averaging 4.6x.

Following the major acquisition of physiotherapy clinic group Back In Motion, Healthia has used $112.5 million on acquisitions for FY22, their activities have been well supported by shareholders who backed the Company during a recent capital raise.

Despite COVID and flood related impacts, Healthia has managed to maintain its outlook on previous earnings guidance, expecting an annualised EBITDA portfolio of $40 million at the start of FY23, almost double the $21.4 million they reported in FY21.

With only 104 clinics under their banner when they commenced trading on the ASX in 2018, Healthia has undergone significant growth over the past few years of 200%, now boasting a portfolio of more than 300 allied health businesses, and counting. Seeking to expand services and enhance cross referral opportunities, Healthia has recently branched into audiology, and is co-locating audiologists within optometry clinics to provide additional services covered by Medicare and private health insurance that service Australia’s aging population. The acquisition of specific hand therapy clinics opens up another opportunity for cross referrals from physiotherapy and occupational therapy services in the Healthia network.

Interest from clinicians to join Healthia is strong, and the Company will be drawing on this as they continue growth via strategic acquisition, fully expecting to deploy another $20 million on new acquisitions in FY23.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
*Owners of this website are shareholders in a company mentioned in this article and have been engaged by them to assist in investor communications
  •  
  •  
  •  
  •  
  • asx hla
  • back in motion
  • bay hand therapy
  • hand therapy
  • healthcare
  • healthia
  • Wesley Coote
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.